EORTC Quality of Life Group participating at the ISOQOL 2025 Conference

The European Organisation for Research and Treatment of Cancer (EORTC) is proud to announce its participation as a Gold Sponsor at the International Society for Quality of Life Research (ISOQOL) 2025 Annual Conference, reaffirming its commitment to advancing patient-centred outcomes in oncology research. The conference is taking place from 22nd to 25th October in Milwaukee, USA.

As part of this sponsorship, EORTC is supporting the plenary session entitled: “Breaking Tradition: Disrupting Quality of Life Research with AI”. This session will explore the expected impact of Artificial Intelligence (AI) on the field of quality of life research.

In addition, as one of the leaders in the field of development and validation of patient-reported outcome (PRO) measures, the EORTC Quality of Life Group (QLG) will showcase its latest research through a series of impactful abstracts presented at the conference:

• Kim Cocks: Updating the EORTC QLQ-MY20 module for multiple myeloma (Oral presentation)
  Preliminary findings from qualitative interviews with patients and healthcare professionals, that will inform the ongoing update of the EORTC QLQ-MY20 module, ensuring its continued relevance and responsiveness to evolving treatment settings.
• Lotte van der Weijst: Assessing the relevance of HRQoL questionnaires in Non-Small Cell Lung Cancer (Poster)
  This study aims to evaluate the relevance of health-related quality of life (HRQoL) questionnaires – especially the EORTC QLQ-C30 and the associated lung cancer module QLQ-LC29 – in capturing treatment-induced adverse events in Non-Small Cell Lung Cancer (NSCLC).
• Dagmara Kuliś: Accelerating ePRO deployment: Insights from copyright review analysis (Poster)
  This study explores the impact of copyright holder reviews on ePRO implementation timelines and supports streamlined processes, including the use of pre-approved libraries and ePRO guidelines, to facilitate faster deployment of PRO measures in studies.
• Sandra Nolte: Evaluating the psychometric properties of EORTC item Q168 (Poster)
  This study investigates the validity of using a single-item measure of side effect burden, such as the EORTC item Q168 (“To what extent have you been troubled with side-effects from your treatment”), both in cancer clinical trials and as part of routine care.
• Claire Piccinin: Developing the EORTC-PRO-AE inventory (Poster)
  Building on a prior mapping of EORTC Item Library content to the Common Terminology Criteria for Adverse Events (CTCAE), this project aims to refine the linking to capture symptomatic Adverse Events (AEs) and to introduce the EORTC-PRO-AE inventory — a comprehensive tool to facilitate the use of EORTC items for symptomatic AE assessment.

For an overview of the abstracts, as well as date and time of presentations, please consult the table below.

For more information about the EORTC Quality of Life Group projects, please click here.

We look forward to seeing you at ISOQOL 2025!

The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.

The EORTC Quality of Life Group (QLG) strives to improve health-related quality of life (HRQoL) of cancer patients, through dedicated research and the use of HRQoL measures within cancer clinical trials and clinical practice. HRQoL constitutes an important aspect of cancer research and care: it gives a voice to patients, putting their experience at the forefront. The QLG is part of the European Organisation for Research and Treatment of Cancer (EORTC).

Caroline Hance (EORTC QLG Communications)
caroline.hance@eortc.org